King Wealth Management Group Purchases 30,000 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

King Wealth Management Group boosted its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 17.1% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 205,000 shares of the company’s stock after acquiring an additional 30,000 shares during the period. King Wealth Management Group’s holdings in Teva Pharmaceutical Industries were worth $3,436,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the company. Harel Insurance Investments & Financial Services Ltd. increased its stake in shares of Teva Pharmaceutical Industries by 51.4% in the second quarter. Harel Insurance Investments & Financial Services Ltd. now owns 33,390,327 shares of the company’s stock worth $559,622,000 after purchasing an additional 11,334,780 shares during the period. Phoenix Financial Ltd. increased its position in Teva Pharmaceutical Industries by 31.7% in the 2nd quarter. Phoenix Financial Ltd. now owns 37,761,444 shares of the company’s stock worth $632,882,000 after buying an additional 9,094,372 shares during the period. Nuveen LLC bought a new position in Teva Pharmaceutical Industries in the 1st quarter worth approximately $40,827,000. Assenagon Asset Management S.A. lifted its holdings in shares of Teva Pharmaceutical Industries by 41.1% during the second quarter. Assenagon Asset Management S.A. now owns 8,445,992 shares of the company’s stock worth $141,555,000 after buying an additional 2,462,064 shares during the last quarter. Finally, Ion Asset Management Ltd. boosted its position in shares of Teva Pharmaceutical Industries by 6.5% in the first quarter. Ion Asset Management Ltd. now owns 39,033,500 shares of the company’s stock valued at $599,945,000 after acquiring an additional 2,383,500 shares during the period. 54.05% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Trading Down 1.1%

Shares of TEVA stock opened at $25.55 on Friday. Teva Pharmaceutical Industries Ltd. has a 52-week low of $12.47 and a 52-week high of $26.38. The stock has a market cap of $29.30 billion, a price-to-earnings ratio of -159.69, a P/E/G ratio of 1.11 and a beta of 0.70. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.77 and a current ratio of 1.06. The firm has a fifty day moving average of $20.26 and a 200-day moving average of $18.13.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Wednesday, November 5th. The company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.68 by $0.10. The business had revenue of $4.48 billion for the quarter, compared to analyst estimates of $4.36 billion. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The firm’s revenue was up 3.4% on a year-over-year basis. During the same period in the previous year, the business earned $0.69 EPS. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.550-2.650 EPS. On average, equities research analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on TEVA shares. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Saturday, October 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, October 8th. UBS Group boosted their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock a “buy” rating in a report on Wednesday, September 24th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Teva Pharmaceutical Industries from $26.00 to $28.00 and gave the company an “overweight” rating in a research report on Thursday, November 6th. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $25.86.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 200,000 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $24.11, for a total transaction of $4,822,000.00. Following the sale, the director directly owned 495,000 shares of the company’s stock, valued at approximately $11,934,450. The trade was a 28.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.